SALT LAKE CITY, Aug. 9, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its fourth fiscal quarter and fiscal year ending June 30, 2011. Revenue for the fourth fiscal quarter increased 14 percent over the same period in the prior year to $107.4 million and resulted in fiscal year revenue of $402.1 million, an increase of 11 percent over the $362.6 million reported for fiscal 2010.
